Summer 2026

Graduate Business Insights & Analytics Data Scientist – Intern

Posted on 3/4/2026

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

Compensation Overview

$20.67 - $52.88/hr

+ Bonus

Indianapolis, IN, USA

In Person

Category
Data & Analytics (1)

Get referred to Lilly USA

See people who can refer or advise you

Requirements
  • Pursuing a PhD in Statistics, Economics, Computer Science, Operations Research, Finance, Mathematics or other related quantitative field.
  • Proficiency in at least one analytical programming tool (Python or R)
  • Competency in standard database concepts and ability to directly query and join tables via code (E.g.: SQL, Tidyverse, Pandas)
  • Research experience in one or more of the following: Machine Learning/Artificial Intelligence, Non-linear Dimension reduction, Clustering and other unsupervised techniques, Computer Vision, Causal AI/inference, Time Series (multivariate and ML approaches preferred), Survival Analysis, Natural Language Processing
  • Strong analytical skills coupled with business acumen, and an ability to think strategically in an ambiguous environment
  • Experience with healthcare data is a plus.
  • Excellent communication (written & verbal), interpersonal influencing skills and prioritization skills with attention to detail
  • Ability to translate technical work for business partners.
Responsibilities
  • Collaborating with commercial teams to identify, scope, and execute analytic efforts that answer business questions, solve business needs, and add business value. Examples include estimating marketing channel effectiveness, improving customer engagement and identifying barriers to care.
  • Suggesting innovations to current approaches and possible future projects
  • Communicating insights to empower key stakeholders to inform decision-making
  • Maintaining a broad understanding of sales and marketing and be fully engaged with business teams, bringing an objective voice to the table, and facilitating decisions grounded in data
  • Engaging with other analytics team members to review and provide feedback on the analytics work being done, and be willing to seek feedback from other team members about your own work
  • Staying current with respect to data science methodology, to maintain proficiency in applying new and varied methods, and to be competent in justifying methods selected

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Get referred to Lilly USA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. access and payer trends drive results, since 67% of 2024 revenue came domestically.[2]
  • Obesity and sleep-apnea prescribing can extend tirzepatide growth beyond diabetes.[2][8]
  • Verzenio provides a meaningful oncology growth leg, contributing 9% of 2025 revenue.[2]

What critics are saying

  • Tirzepatide concentration exposes Lilly to payer pushback and prescribing slowdowns.[2]
  • Novo Nordisk's obesity and diabetes franchise forces price competition and access concessions.[8]
  • Manufacturing, quality, or counterfeit problems directly constrain supply and damage trust.[1][2]

What makes Lilly USA unique

  • Lilly sells prescription medicines across diabetes, oncology, immunology, and neuroscience.[4][8]
  • Tirzepatide products dominate revenues, with Mounjaro and Zepbound at 56% in 2025.[2]
  • Lilly has global reach, with products sold in approximately 125 countries.[2]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

0%
NAVLIN by EVERSANA
Jul 8th, 2026
Florida Hospital sues Eli Lilly over withheld 340B discounts.

Florida Hospital sues Eli Lilly over withheld 340B discounts. 08 Jul 2026 Listen to Article NAVLIN Brief * Tampa General Hospital has filed a lawsuit against Eli Lilly over the manufacturer's decision to stop providing 340B discounts to hospitals that fail to comply with its data requirements * Earlier this year, Eli Lilly announced that it would require 340B covered entities to provide claims-level data for all 340B dispenses, including in-house pharmacy dispensing * Tampa General Hospital is now the first provider to sue Lilly over the policy, claiming that the drugmaker's decision to stop providing 340B discounts violates Florida's Deceptive and Unfair Trade Practices Act The Details

Pharma Focus Asia
Jun 19th, 2026
Charles River joins Lilly TuneLab to optimize AI/ML platform through nonclinical testing expertise.

Charles River joins Lilly TuneLab to optimize AI/ML platform through nonclinical testing expertise. Friday, June 19, 2026 Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing services to TuneLab companies. "The combination of Charles River's decades-long expertise in nonclinical testing with TuneLab's innovative AI/ML models will support the accelerated development of innovative therapeutics," said Dr. Namandjé N. Bumpus, Chief Science and Innovation Officer, Charles River. "TuneLab's collaborative AI platform democratizes access to pharma-grade tools, relieving a substantial resource burden for biotechs. By layering in Charles River's industry-leading hands-on research experience, TuneLab participants have access to additional validation that supports discovery decision-making." Standardizing protocols with nonclinical testing across the TuneLab ecosystem should enable the AI/ML models to learn more efficiently from the ongoing contributions, improving the models further and increasing the efficiency of the TuneLab platform. Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities. Charles River remains committed to advancing the validation and acceptance of new approach methodologies (NAMs), including through its Alternative Methods Advancement Project(TM)(AMAP(TM) initiative. Together with clients, regulators, and industry, NAMs provide a foundation for a future where more patients gain access to life-saving treatments - safely, swiftly, and with reduced reliance on animal use in research where scientifically appropriate. About the Alternative Methods Advancement Project (AMAP) The Alternative Methods Advancement Project (AMAP) is a Charles River-led initiative dedicated to developing New Approach Methodologies (NAMs) and exploring innovative scientific and technological solutions aimed at reducing reliance on traditional animal testing. As “Pharmafocusasi enter the next frontier of drug development, AMAP enables strategic, purpose-driven investment to shape a future in which more patients can access the treatments and medicines they need safely, swiftly, and successfully. AMAP is supported by its global, cross-functional Scientific Advisory Board led by Dr. Namandjé N. Bumpus. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about its unique portfolio and breadth of services, visit www.criver.com. Contacts Charles River Investor Contact: Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected] Charles River Media Contact: Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer 781.222.6168 [email protected]

The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

INACTIVE